Tirzepatide Monotherapy Significantly Reduces HbA1c and Body Weight in Early Type 2 Diabetes

Effective management of type 2 diabetes (T2D) requires robust glycemic control and often weight reduction, yet many patients struggle to achieve these targets with existing therapies. Current standard-of-care often involves multiple medications, which can increase complexity and side effects. Tirzepatide, a dual GLP-1R and GIP-R agonist, offers a novel mechanism to address both hyperglycemia and obesity, making it a promising candidate for early intervention in T2D, particularly in populations where these conditions are prevalent.

This multicenter, randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) enrolled 206 Chinese adults with type 2 diabetes who were treatment-naive for 90 days. Participants were randomized 1:1:1:1 to receive once-weekly 5 mg, 10 mg, or 15 mg tirzepatide or placebo via subcutaneous injection. The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40. Secondary endpoints included body weight changes and safety assessments, with ELISA or similar methods for biomarker analysis.

All tirzepatide doses demonstrated significantly greater reductions in HbA1c and body weight compared to placebo at week 40. Under the efficacy estimand, mean HbA1c reductions from baseline were -2.17% (5 mg), -2.06% (10 mg), and -2.15% (15 mg) versus -0.13% for placebo. Treatment differences versus placebo were -2.04% (95% CI: -2.46, -1.63), -1.93% (95% CI: -2.35, -1.51), and -2.02% (95% CI: -2.44, -1.60) for the 5 mg, 10 mg, and 15 mg groups, respectively (p < 0.001 for all comparisons). Body weight reductions were also significant:

Mean body weight reductions were -6.0 kg (5 mg), -6.1 kg (10 mg), and -9.7 kg (15 mg) versus -1.0 kg for placebo (p < 0.001 for all comparisons). The most common treatment-emergent adverse events were gastrointestinal, consistent with previous trials, and there was no clinically significant (<54 mg/dL) or severe hypoglycemia observed.